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In the search for new compounds with antitumor activity, coordination complexes with different metals are being
studied by our group. This work presents the synthesis and characterization of six copper complexes with general
stoichiometry [Cu(L-dipeptide)(phen)]·nH2O (were phen = 1,10-phenanthroline) and their cytotoxic activities
against tumor cell lines. To characterize these systems, analytical and spectroscopic studies were performed in
solid state (by UV–visible, IR, X-ray diffraction) including the crystal structure of four new complexes (of the six
complexes studied): [Cu(Ala-Phe)(phen)]·4H2O, [Cu(Phe-Ala)(phen)]·4H2O, [Cu(Phe-Val)(phen)]·4.5H2O and
[Cu(Phe-Phe)(phen)]·3H2O. In all of them, the copper ion is situated in a distorted squared pyramidal environment.
The phen ligand is perpendicular to the dipeptide, therefore exposed and potentially available for interaction with
biologicalmolecules. In addition, for all the studied complexes, structural information in solutionusing EPR andUV–
visible spectroscopieswere obtained, showing that the coordination observed in solid state ismaintained. The lipo-
philicity, DNA binding and albumin interaction were also studied. Biological experiments showed that all the com-
plexes induce cell death in the cell lines: HeLa (human cervical adenocarcinoma), MCF-7 (humanmetastatic breast
adenocarcinoma) and A549 (human lung epithelial carcinoma). Among the six complexes, [Cu(Ala-Phe)(phen)]
presents the lowest IC50 values. Taken together all these data we hypothesize that [Cu(Ala-Phe)(phen)] may be a
good candidate for further studies in vivo.
© 2014 Elsevier Inc. All rights reserved.
1. Introduction
The usefulness of coordination metal complexes in cancer chemo-
therapy has been demonstrated by Cisplatin which is one of the most
used anticancer drugs against a wide range of malignancies. However,
signiﬁcant side effects and increasing drug resistance have limited its
clinical applications [1].
In the search for new compounds with antitumor activity one strat-
egy is based on studying coordination compoundswith essential metals
as a central atom, aimed at ﬁnding compounds with less severe side
effects and awider spectrumof action than Cisplatin. In this context,mul-
tiple Cu(II) compounds have been studied, with 1,10-phenanthroline
(phen), thiosemicarbazone, or salicylate, and its derivatives as ligands,
presenting many of them antitumor activity [2,3]. Outstanding examples
of active Cu-complexes are the coordination compounds known as
Casiopeinas®, developed by L. Ruiz and co-workers, two of which are
already approved for clinical trials as antitumor drugs, [(Cu(II))(4,7-
dimethyl-phen)(glycinate)(NO3)(H2O)] and [(Cu(II))(4,4′-dimethyl-
2,2′-bipyridine)(acetylacetonate)(NO3)(H2O)] [4]. The proposedmech-
anism of action of these complexes involves oxidative damage, due to
intracellular formation of reactive oxygen species (ROS) and DNA inter-
action, leading to apoptosis of the cells [5]. In addition to Cu(II) com-
plexes, Cu(I) complexes also show antitumor activity. For instance,
the phosphine copper(I) complex, [Cu(thp)4][PF6], presents strong
antiproliferative effects, inducing 26S proteasome inhibition follow-
ed by parapoptotic death of the cells [6].
Regarding phen homoleptic Cu-complexes, [Cu(phen)2]+ is one of
the most studied Cu-complex from a biochemical point of view. There
is large amount of evidence supporting its DNA noncovalent binding
to the minor groove of the double stranded DNA, cleaving DNA at its
binding region [7,8]. [Cu(phen)2]2+ also intercalates in the minor
groove of DNA, and shows nuclease activity [9,10]. In addition, a number
of heteroleptic phen-containing Cu(II) complexes show DNA binding
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and nuclease activity, thus preventing cellular growth [2,3]. On the
other hand, Cu-dipeptide complexes, previously studied by our research
group, coordinate to DNA and present some cytotoxic activity [11].
Moreover, some ternary complexes with general formula Cu(II)-L-
dipeptide-phen, have been prepared an characterized [12–16], how-
ever, to the best of our knowledge, their cytotoxic activity has not
been reported to this date.
With the aim of ﬁnding new copper compounds with improved
cytotoxic activity we took as a starting point the cytotoxicity presented
by Cu-dipeptide complexes. To improve the activity, we introduced
phen as a co-ligand, preparing ternary Cu-L-dipeptide-phen complexes.
The introduction of phen could improve the lipophilicity of the com-
plexes, thus improving cellular uptake. In addition, phen could work
as an ancillary ligand making these complexes intercalate to DNA
increasing its cytotoxic activity.We chose a set of L-dipeptides (L-dipep-
tides = Gly-Val, Ala-Gly, Ala-Phe, Phe-Ala, Phe-Val and Phe-Phe)
among the previously studied so as to cover a range of side chains as
well as of lipophilicity. In order to study the inﬂuence of the side chain
position we included isomeric dipeptides (L-Ala-L-Phe and L-Phe-
L-Ala). Firstly, the obtained complexes were characterized both in
solid state and in aqueous solution. Secondly, their lipophilicity and
DNA interaction were measured in order to assess the effect of the
introduction of the phen. Finally, their cytotoxicity was evaluated
against HeLa (human cervical adenocarcinoma), MCF-7 (human
metastatic breast adenocarcinoma) and A549 (human lung epithelial
carcinoma).
2. Experimental
Reagents for synthesis and biochemical studieswere used as commer-
cially available: Copper salts (Fluka), L-dipeptides, 1,10-phenanthroline
(SIGMA) and Calf thymus DNA (CT-DNA, SIGMA).
2.1. Synthesis of the complexes and analytical characterization
Ternary Cu–dipeptide–phenanthroline complexeswhere L-dipeptide:
Gly-Val, Ala-Gly, Ala-Phe, Phe-Ala, Phe-Val or Phe-Phe were obtained as
follows: 0.1 mmol of dipeptide was dissolved in the appropriate volume
of warm water (50–200 mL) and 0.1 mmol of CuSO4·5H2O was added.
The pH was adjusted to 7 with a NaOH solution. A solution of 0.1 mmol
of phen in 10 mL of ethanol was added. The compounds were isolated
by evaporation at 50–60 °C, until blue crystals were formed. Yield
60–80%. To obtain adequate single crystals, a small amount of the
solution was allowed to slowly evaporate at room temperature.
Blue-purple crystals were obtained for [Cu(Ala-Phe)(phen)]·4H2O,
[Cu(Phe-Phe)(phen)]·3H2O and [Cu(Phe-Ala)(phen)]·4H2O, and
green ones for [Cu(Phe-Val)(phen)]·4.5H2O.
Elemental analysis: [Cu(Gly-Val)(phen)]·6.5H2O (C1): Calc. for
C19H33CuN4O9.5: C, 42.82, N, 10.51, H, 6.24 Found: C, 42.80, N, 10.37,
H, 5.85; [Cu(Ala-Gly)(phen)]·5H2O (C2): Calc. for C17H26CuN4O8: C,
42.72, N, 11.72, H, 5.48 Found: C, 42.54, N, 11.73, H, 5.74; [Cu(Ala-
Phe)(phen)]·4H2O (C3): Calc. for C24H30CuN4O7: C, 52.40, N, 10.19, H,
5.50 Found: C, 51.85, N, 10.17, H, 5.12; [Cu(Phe-Ala)(phen)]·4H2O
(C4): Calc. for C24H30CuN4O7: C, 52.40, N, 10.19, H, 5.50 Found: C,
52.11, N, 10.22, H, 5.68; [Cu(Phe-Val)(phen)]·4.5H2O (C5): Calc. for
C26H35CuN4O7.5: C, 53.19, N, 9.54, H, 6.01 Found: C, 53.21, N, 9.53, H,
5.45; [Cu(Phe-Phe)(phen)]·3H2O (C6): Calc. for C30H32CuN4O6: C,
59.25, N, 9.21, H, 5.30 Found: C, 59.36, N, 9.38, H, 5.21.
2.2. Physical measurements
Chemical analyses for carbon, nitrogen, hydrogen and sulfur were
performed with a Carlo Erba analyzer. Infrared spectra were recorded
with a Bomen FT-IR spectrophotometer from 4000 to 400 cm−1 using
KBr disks.
UV–visible (UV–vis) spectra of the complexes' solutions were car-
ried out with a Milton Roy Spectronic 3000 spectrophotometer, using
1 cm path length quartz cells.
X-band (9.5 GHz) EPR measurements were carried out on aqueous
solutions using a JEOL JES-FA200 spectrometer and a cavity with
100 kHzﬁeldmodulation.Measurementswere performed at room tem-
perature and experimental parameters were adjusted to avoid signal
saturation and line shape distortions. The g- and A-values were obtain-
ed from spectral simulations using the Easyspin software [17].
2.3. Crystal structure determination
Data from suitable single crystals were collected at 100.0(2) K for
complexes C3, C4, C6 and 293.0(2) K for C5 on an Enraf-Nonius FR590
Kappa-CCD diffractometer using graphite monochromated MoKα radi-
ation (0.71073 Å). The collection software used was Bruker AXS Collect
software, and data processing was made with HKL Denzo-Scalepack
program suite. The structures were solved by direct methods using
the SIR-92 program [18] and the model reﬁned with SHELXL-2013
[19]. Gaussian absorption correction was applied for complexes C4
and C6, whereas multi-scan correction was applied to complexes C3
and C5 [20,21]. SHELXL-2013 and ORTEP-3 programs were used within
theWinGX [22] interface to preparematerials for publication.Molecular
structure graphics were prepared using MERCURY program [23].
All non-hydrogen atomswere reﬁnedusing anisotropic displacement
parameters. Hydrogen atoms of C\H groups were stereochemically po-
sitioned and reﬁned isotropically with the riding-model setting their
thermal parameter as 1.20 times the equivalent isotropic displacement
parameter of the C atom they are bonded to. Whereas, amino hydrogen
andwater hydrogen atomswere found in the difference Fouriermap, po-
sitionally ﬁxed and their thermal parameters set to 1.2 times the equiv-
alent Uiso in the case of amino groups and 1.5 times for the O\H bonds.
In the particular case of C5 the solvent contribution to the scattering was
removed with the SQUEEZE routine in PLATON [24] due to the extent of
solvent disorder, the formula mass and density informed for this com-
plex don't account for the solvent present. The electron count in cell
void volume ran with squeeze gives a total of 66 electrons equivalent
to 6.5 water molecules per unit cell. Summary of the crystallographic
data, experimental details and reﬁnement results are listed in Table 1.
2.4. Lipophilicity tests
Lipophilicity was studied through the determination of the partition
coefﬁcient of the complexes in n-octanol/physiological solution (0.9%
NaCl in water). The copper concentration was measured by atomic
bsorption spectroscopy using a PerkinElmer 5000 instrument, with a
Photron lamp for copper analysis [25].
2.5. DNA binding: UV absorption titration experiments
Absorption titration measurements were carried out varying the
concentration of calf thymus-DNA (CT-DNA) from 0 to 25 μM, while
keeping the metal complex concentration constant at 20 μM in
phosphate buffer solution (pH = 7.4). The intrinsic binding constant
(Kb) for the interaction of the complexes with CT-DNAwas determined
from the [DNA]/(εa− εf) versus [DNA] plot using absorption spectral
titration data and the following equation: [DNA] / (εa− εf) = [DNA] /
(εb − εf) + 1 / Kb(εb− εf) (Eq. 1) where [DNA] is the concentration
of DNA, εa is the apparent absorption coefﬁcients, εf and εb correspond
to Aobs/[Cu], the extinction coefﬁcient for the free copper(II) complex
and the extinction coefﬁcient for the copper(II) complex in the fully
bound form, respectively. The Kb value is given by the ratio of the
slope to the intercept [26]. Solutions of CT-DNA in buffer gave a ratio
of UV absorbance A260/A280 of 1.8–1.9, indicating that the DNA was
sufﬁciently free of protein [26]. The stock solution of DNA prepared in
buffer was kept at 4 °C and used within 4 days. The concentration of
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DNA was determined from the intensity of the 260 nm band with a
known extinction coefﬁcient value (ε260 = 6600 M−1 cm−1). Cu-
complexes were stable in the buffer solution in the assay conditions.
2.6. Albumin binding studies
Albumin binding studies were performed by tryptophan ﬂuores-
cence quenching experiments. Bovine serum albumin (BSA, Sigma)
and copper complexes solutions were prepared in Tris–HCl (0.1 M,
pH 7.4) buffer to attain a ﬁnal concentration of 6 μM on BSA and com-
plexes in the range 20–100 μM. BSA was titrated by addition of copper
complex solution. Measurements were carried out on a Shimadzu
RF-5301PC spectroﬂuorophotometer where ﬂuorescence emission in-
tensity at 348 nm was registered after excitation at 280 nm at 25 °C.
The Linweaver–Burk equation ((F0− F)−1 = F0−1 + Ka−1 F0−1[Q]−1)
for static quenching was used to determine the constant binding of
the copper complexes to BSA [27].
2.7. Cytotoxicity studies
Cell lines were obtained from the American Type Culture Collection
(ATCC): HeLa (CCL-2™, human cervical adenocarcinoma), MCF-7 (HTB-
22™, human metastatic breast adenocarcinoma) and A549 (CCL185™,
human lung epithelial carcinoma). HeLa andMCF-7 cells were grown in
Dulbecco's modiﬁed Eagle medium (DMEM) and A549 was grown in
RPMI Medium containing L-glutamine and supplemented with 10%
fetal bovine serum (FBS). The cells were removed enzymatically from
ﬂasks using 0.01% Trypsin-EDTA solution. Cultured cells were incubated
at 37 °C on 5% CO2 atmosphere for 48 h, containing aqueous solutions of
the Cu complexes (ﬁnal concentrations ranging from 1 to 50 μM). Cell
viability in response to the complexes was determined by colorimetric
assay using Cell Counting Kit — 8 (Fulka) on 15.000 cells grown in 96-
well plates. The kit utilizes a water-soluble tetrazolium salt that is re-
duced by dehydrogenases in cells to give a yellow colored product
(formazan). The absorbance of converted dye was measured at 450 nm
using a microplate reader. The amount of the formazan dye generated
by the activity of dehydrogenases in cells is directly proportional to the
number of living cells. The IC50 was estimated from the semi logarithmic
dose–response curves. Cu-complexes solutions were prepared by dis-
solving the corresponding solid complexes, previously characterized, in
water and then sterilized by ﬁltration.
3. Results
3.1. Crystal structures
The crystal structures of four new complexes [Cu(Ala-Phe)(phen)]·
4H2O, [Cu(Phe-Ala)(phen)]·4H2O, [Cu(Phe-Val)(phen)]·4.5H2O and
[Cu(Phe-Phe)(phen)]·3H2O were obtained. The molecular structure of
the [Cu(Ala-Phe)(phen)]·4H2O compound with anisotropic displace-
ment ellipsoids (50% probability) and numbering scheme is shown
in Fig. 1 (Figs. for complexes C4–C6 are in supplemental material).
All the complexes present similar coordination sphere, where the cop-
per ion is situated in a distorted squared pyramidal environment,
equatorially coordinated to two N and one O atom from the dipeptide,
and one N atom of the phen. The coordination sphere is completed by
one N atom of the phen in the apical position. Table 2 show bond dis-
tances and angles around the copper atom for complex [Cu(Ala-
Phe)(phen)]·4H2O (Tables for complexes C4–C6 are in supplemental
material). Bond lengths agree well with those found in similar com-
plexes. The phen ligand presents a usual bite distance (around 2.7 Å)
and angle (77–78°) and it is in a nearly orthogonal position with the
Cu-peptide moiety. Therefore, the phen ligand is exposed and it might
interact with biological molecules as DNA. All these characteristics are
similar to those for the previously reported Cu-L–dipeptide–phen com-
plexes: [Cu(Gly-Gly)(phen)]·3H2O [12], [Cu(Tyr-Gly)(phen)]·3H2O
[13], [Cu(Ala-Gly)(phen)]·3.5H2O, [Cu(Val-Gly)(phen)] and [Cu(Gly-
Trp)(phen)]·2H2O [16].
In spite of the common features, there are also some differences ob-
served in the crystal structure. In complexes C3–C5 all the molecules
Table 1
Crystal data and structure reﬁnement for complexes 3-6.
Compound C3 C4 C6 C5
Empirical formula C24H30CuN4O7 C24H30CuN4O7 C30H31.75CuN4O5.9 C52H52Cu2N8O6
Fw 550.07 550.06 605.89 1012.09
Wavelength (Å) 0.71073
Crystal system Orthorhombic Monoclinic Triclinic Orthorhombic
Space group P21 21 21 C2 P1 P 2 21 21
Unit cell dimensions a = 9.5074(3) Å a = 22.5305(4) Å a = 12.33330(10) Å a = 12.569(5) Å
b = 12.2813(3) Å b = 11.5646(2) Å b = 14.14090(10) Å b = 20.953(5) Å
c = 21.3197(7) Å c = 10.7493(2) Å c = 18.0314(2) Å c = 21.327(5) Å
α = 90° α = 90° α = 110.1530(10)° α = 90°
β = 90° β = 116.108(1)° β = 101.9520(10)° β = 90°
γ = 90° γ = 90° γ = 92.4660(10)° γ = 90°
Volume (Å3) 2489.36(13) 2515.02(8) 2865.73(5) 5617(3)
Z 4 4 4 4
ρcalc.(mg/m3) 1.468 1.453 1.409 1.197
Abs. coeff. (mm−1) 0.928 0.919 0.812 0.808
F(000) 1148.0 1148 1263.0 2104
Cryst. size (mm3) 0.194 × 0.106 × 0.09 0.48 × 0.30 × 0.12 0.27 × 0.14 × 0.12 0.340 × 0.201 × 0.197
Θ range (°) 3.312 to 25.024° 3.23 to 26.60° 3.140 to 27.420° 3.026 to 26.359°
Miller indices −11 ≤ h ≤ 11, −28 ≤ h ≤ 28 −15 ≤ h ≤ 15 −15 ≤ h ≤ 15
−14 ≤ k ≤ 14 −14 ≤ k ≤ 14 −18 ≤ k ≤ 17 −26 ≤ k ≤ 26
−25 ≤ l ≤ 25 −12 ≤ l ≤ 13 −23 ≤ l ≤ 23 −21 ≤ l ≤ 26
Reﬂections collected 20757 14750 83426 66412
Independent reﬂections 4357 [R(int) = 0.075] 5178 [R(int) = 0.0329] 24304 [R(int) = 0.0554] 11410 [R(int) = 0.0467]
Completeness 97.1% 99.0% 99.8% 99.6%
Max. and min. transmission 0.990 and 0.667 0.909 and 0.743 0.919 and 0.843 1.054 and 0.940
Data/restraints/parameters 4357/0/325 5178/1/326 24304/3/1479 11410/0/613
Goof 1.036 1.066 1.042 1.077
R indices [I N 2σ (I)] R1 = 0.0389, wR2 = 0.0865 R1 = 0.0320, wR2 = 0.0821 R1 = 0.0429, wR2 = 0.1008 R1 = 0.0423, wR2 = 0.1074
R indices (all data) R1 = 0.0543, wR2 = 0.0921 R1 = 0.0351, wR2 = 0.0847 R1 = 0.0508, wR2 = 0.1048 R1 = 0.0459, wR2 = 0.1089
Flack parameter 0.029(8) −0.007(9) 0.002(3) 0.040(5)
Largest diff. peak and hole (e.Å−3) 0.397 and−0.338 0.419 and−0.590 0.732 and−0.578 0.286 and−0.520
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present similar orientation of the phenyl groups, while in C6 there are
four different arrangements of the ligands. As a geometry distortion de-
scriptor the τ factor (which varies from 0 for perfect square pyramidal
to 1 for trigonal-bipyramid geometry) [28] was calculated for all copper
centers and results are listed in Table 3. The contribution of the trigonal-
bipyramid geometry ranges from 4 to 35%.
In complexes C3–C5 all molecules participate in intramolecular
C\H⋯π interaction, whereas in the C6 complex only two out of the
four molecules per asymmetric unit participate in this type of interac-
tion. This interaction was evaluated as the distance of the nearest H
atom of the Phe to the centroid of the nearest ring of the phen. Complex
C3 presents the shortest centroid to Phe's H distance, whereas the lon-
gest distances are found in the C6 complex.
3.2. Infrared spectra of the complexes
The spectra of the complexes present several common features. For
instance, a broad, very strong peak around 1600 attributed to ν(C_O)
+ ν(C\N)+ νas(COO), characteristic of the coordinated dipeptidemoi-
ety [29–31]. Absorption peaks corresponding to ring stretching frequen-
cies of the phen are modiﬁed in relation to the free phen and appear at
1515 cm−1 and 1428 cm−1, in agreement with the coordination of the
phen. Other characteristic bands, due to the rocking of the C\H groups
of the phen, appear from 1200 cm−1 to 720 cm−1, as shown in Table 4.
3.3. Characterization in aqueous solution: UV–vis and EPR spectra
Cu(II) complexes are labile in solution, therefore they may change
their coordination sphere easily, and for instance, the structure ob-
served in solid state may not be the structure of the species present in
solution, where they exert their biochemical and biological effects. In
order to check if the structure observed in solid state is conserved in
aqueous solutions, dissolutions of the solids previously obtained were
prepared, and UV–vis and EPR spectra were recorded and analyzed.
Table 5 presents the wavelength of the maxima of the visible spectra
of the complexes. The spectrum of all the complexes presents a broad
peak around 630 nm with a shoulder at about 850 nm. This shoulder
is characteristic of copper in pentacoordinated environments. More-
over, the wavelength of the maximum is about 50 nm lower than ex-
pected if the complex had an octahedral arrangement with an N3O
equatorial chromophore [32]. This red shift is characteristic of the
pentacoordination on copper complexes, and the value of the shift is
in agreement with the observed shift for one N axially coordinated
[33]. The molar absorption coefﬁcients of these complexes are higher
than those observed in homoleptic Cu–dipeptide complexes, indicating
a less symmetric environment [14,30,31].
The X-band EPR spectra of aqueous solutions of the complexes
[Cu(Ala-Gly)(phen)], [Cu(Ala-Phe)(phen)] and [Cu(Phe-Ala)(phen)]
measured at liquid nitrogen temperature present the characteristic
Fig. 1. ORTEP representation of the asymmetric unit of [Cu(Ala-Phe)(phen)]·4H2O (C3). Water molecules were omitted for simplicity.
Table 2
Selected bond lengths (Å) and angles (°) for complex C3.
C3
Cu(1)–N(4) 1.905(4)
Cu(1)–O(3) 1.990(3)
Cu(1)–N(3) 2.029(4)
Cu(1)–N(2) 2.037(4)
Cu(1)–N(1) 2.225(4)
N(4)–Cu(1)–O(3) 82.98(15)
N(4)–Cu(1)–N(3) 83.38(16)
O(3)–Cu(1)–N(3) 164.89(15)
N(4)–Cu(1)–N(2) 162.33(16)
O(3)–Cu(1)–N(2) 92.91(14)
N(3)–Cu(1)–N(2) 98.14(16)
N(4)–Cu(1)–N(1) 119.55(15)
O(3)–Cu(1)–N(1) 92.92(14)
N(3)–Cu(1)–N(1) 99.46(15)
N(2)–Cu(1)–N(1) 77.71(15)
Table 3
τ value and C\H⋯π (centroid–H distance).
Complex τ value C\H⋯π (centroid–H distance)
C3 0.04 2.568
C4 0.15 3.163
C5 0.05–0.06 2.898, 3.242
C6 0.03–0.35 2.732, 2.963, 3.163, 3.271a
a Only two of the molecules out of four per asymmetric unit participate in C\H⋯π
interactions.
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four-line multiplet, assigned to the hyperﬁne interaction between the
magnetic moments associated with the electron (S = 1/2) and the
nuclear (I = 3/2) spins, centered around a magnetic ﬁeld value
(ca. 290 mT) corresponding to the parallel principal value of the
magnetic g-tensor (g// of ca. 2.18) (Fig. S4). The multiplet is not re-
solved in the perpendicular direction of the g-tensor thus giving rise
to the broad feature around 320 mT in the spectra. These lineshape
patterns observed in all spectra are characteristic of monomeric cop-
per species in frozen solution. To gain further information regarding
structural and magnetic features of the complexes, the spectra were
simulated by using routines available in the software EasySpin. The
spin Hamiltonian included terms that took into account the Zeeman
and hyperﬁne interactions, which gave rise to g- and A-values, respec-
tively (Table 5). It can be seen from the calculated values that g//
is slightly lower than those of homoleptic Cu–dipeptide complexes,
which is an indication of pentacoordination as observed for other cop-
per complexes [14]. To check whether the complexes maintain their
monomeric state also at room temperature, EPR spectra were collected
and showed the usual four-linemultiplet, whose shape now reﬂects the
modulation of the hyperﬁne and Zeeman interactions imposed by the
dynamics of the molecule, which results in the four-line pattern with
resonances with varying intensity (Fig. S5).
Therefore, according to this interpretation of the visible spectrum
and the EPR data, the coordination environment of the metal observed
in the solid state is maintained in aqueous solution being the ternary
complex the mayor species in these conditions.
3.4. Lipophilicity
Lipophilicity is a relevant parameter as it plays a role in determin-
ing the kinetic and dynamic behavior of a drug. The common quanti-
tative descriptor of lipophilicity is the octanol–water partition
coefﬁcient, P [34].
Table 6 presents obtained P coefﬁcients. The general trend observed
in the tabulated P-values for [Cu(dipeptide)(phen)] complexes suggests
that lipophilicity increases with ligand complexity. This trend follows a
well known behavior, according to which in homologous series the
partition coefﬁcients increase by the addition of CH2 or phenyl groups.
In spite of this, [Cu(Phe-Ala)(phen)] is slightly more lipophilic than
[Cu(Ala-Phe)(phen)], showing the importance of the overall arrange-
ment of the ligands in the complex in aqueous solution. The P values
are greater than that observed for Cu-dipeptide complexes (where the
most lipophilic is [Cu(Phe-Phe)], P = 0.36).
3.5. DNA binding studies
The absorption spectra of the complex [Cu(Ala-Phe)(phen)] in
the absence and in the presence of CT-DNA are shown in Fig. 2. In the
UV region, the complexes exhibited an intense absorption band at
λmax = 270 nm. Upon the addition of CT-DNA, the absorbance in
this band slightly increases. These spectra were compared with
those calculated as the sum of the spectrum of the complex plus
the spectrum of the DNA (without the complex). These simulated
spectra are more intense than the measured ones. The hypochromic
effect observed in the experimental spectra in relation to the calcu-
lated ones shows that a binding event has occurred which can be at-
tributed to groove binding and or intercalation of the complex to the
DNA [10].
To qualitatively determine the DNA binding strength of the com-
plexes, their intrinsic binding constants (Kb) calculated by Eq. 1 are pre-
sented in Table 7. Their Kb values are lower than that of the classical
intercalator ethidium bromide (1.4 × 106) [35], and similar or higher
than that of the Cu-phen complex ([Cu2(phen)2Cl4], Kb of 4.75 × 104
M−1 [36]) and are in agreementwith an interaction trough groove bind-
ing and partial intercalation, whichmay occur trough partial intercalation
of phenmoiety and of the phenyl ring of the Phe-containing dipeptides. A
similar case of partial intercalation has been proposed recently for a relat-
ed complexwith bipy ([Cu(2,2′-bipyridine)(acetylacetonate)(H2O)]+) by
computational studies [37].
3.6. Albumin binding studies
Preliminary studies of albumin binding were performed. All the
studied complexes bind to albumin in the assay conditions. Table 8
shows the obtained kb. Further studies are necessary to establish the
mode of interaction (Cu binding, interaction of the entire ternary com-
plex trough the phen or the phenyl groups).
3.7. Cytotoxic activity
All complexes show cytotoxic activity against the studied lines of
cancer cells, as observed in Table 9. Among the six studied complexes,
[Cu(Ala-Phe)(phen)], C3, presents the higher activity, with IC50 values
comparable or lower to those presented by other complexes catalogued
as promising antitumor agents [3,38–40]. Moreover, C3 induces MCF-7
cell death at an IC50 = 1 μM being more active than Cisplatin which
Table 4
Wavenumber (cm−1) of common bands in the complexes and in the free phen, as well as their tentative vibrational assignment.
Assignment ν(C_O) + ν(C\N) + ν(COO)as ν(C_C) ν(C_N) ρ(C\H) ρ(C\H) ρ (C\H) ρ(C\H)
phen 1504 1422 1138 1091 854 739
[Cu(Gly-Val)(phen)] 1588 1517 1430 1143 1105 850 725
[Cu(Ala-Gly)(phen)] 1646 h, 1580 1519 1430 1157 1104 849 728
[Cu(Ala-Phe)(phen)] 1589 1517 1428 1142 1102 849 729
[Cu(Phe-Ala)(phen)] 1594 1517 1433 1147 1106 851 729
[Cu(Phe-Val)(phen)] 1624 h, 1590 1517 1427 1143 1104 846 729
[Cu(Phe-Phe)(phen)] 1591, 1576 1515 1428 1140 1105 845 727
Table 5
Wavelength of the maxima of the visible spectra of the complexes and calculated EPR pa-
rameters for the complexes.
Compound λmax (nm)/εM (M−1 cm−1) g// g⊥ A//(mT)
[Cu(Gly-Val)(phen)] 632/97 – – –
[Cu(Ala-Gly)(phen)] 636/99 2.1812 2.0198 15.61
[Cu(Ala-Phe)(phen)] 627/107 2.1835 2.0119 16.44
[Cu(Phe-Ala)(phen)] 634/96 2.1822 2.0156 15.86
[Cu(Phe-Val)(phen)] 630/113 – – –
[Cu(Phe–Phe)(phen)] 631/107 – – –
Table 6
Partition coefﬁcients (P) between n-octanol and physiologic
solution.
Compound P
[Cu(Gly-Val)(phen)] ND
[Cu(Ala-Gly)(phen)] ND
[Cu(Ala-Phe)(phen)] 0.18
[Cu(Phe-Ala)(phen)] 0.30
[Cu(Phe-Val)(phen)] 0.59
[Cu(Phe-Phe)(phen)] 4.12
ND: not detected.
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was shown to induce cytotoxicity at IC50=2 μMat 96 h of treatment for
the same cell line [41].
No correlation can be stated between the IC50, DNA binding (Kb) and
lipophilicity (P). A similar situation was observed on related copper
complexes, where there was no correlation between lipophilicity and
cytotoxic activity, although there was a correlation between lipophilic-
ity and intracellular copper concentration [42].
It can be discussed whether the ternary species are relevant to the
cytotoxic activity or are the binary species the oneswith cytotoxic activ-
ity. Ternary Cu-complexes, when dissolved in water, take part of an
equilibrium, in which different species (ternary and binary) coexist.
For the studied Cu–dipeptide–phen complexes, at 1E-3 M ternary spe-
cies are the mayor component, as discussed previously (Section 3.3).
At the concentration of the IC50 of the most active complex, 1 E-6, and
pH 7.4 it can be still expected a signiﬁcant amount of ternary species
in solution. For instance, as a reference of the stability of these com-
plexes in the Cu–(Gly-Gly)–phen system ternary species account for
only 2% of the Cu while the binary complex Cu–phen for about 75% ac-
cording to published data (Table S3) [13]. This complex is supposed to
be at the lower end of stability for this group of complexes, as it doesn't
present inter-ligand interactions. For the complexes included in this
work stability constants of the ternary complexes are expected to be
higher (theywere notmeasured) based on literature data of related com-
pounds, due to dipeptide side chain-phenanthroline interactions (such as
those observed in solid state) [13,43]. Therefore a higher, signiﬁcant, per-
centage of ternary species is expected in the bioassay conditions.
In addition, dissolutions of ternary complexes are more active than
the [Cu(phen)2]Cl2 complex (which in solution yields mostly
Cu(phen)2+), and the corresponding Cu–dipeptide binary complex
(IC50 50–70 μM in HeLa cells, data not published) suggesting that the
ternary species present are relevant for the antitumor activity.
4. Conclusions
Six ternary copper–dipeptide–phenanthroline complexes (ﬁve of
them new) were synthesized and characterized in solid state and in
solution by analytical and spectroscopicmethods. Four newX-ray struc-
tures are reported. In all of them the copper ion is situated in a distorted
squared pyramidal environment, equatorially coordinated to two N and
one O atom from the dipeptide, and one N atom from the phen. The co-
ordination sphere is completed by one N atom of the phen in the apical
position. The phen ligand is exposed and potentially available for the in-
teraction with biological molecules. According to the spectroscopic
studies, the coordination environment of the metal observed in the
solid state is maintained in aqueous solution.
On the other hand, the lipophilicity of the studied complexes was
modulated by the dipeptides in a range of partition coefﬁcients, being
[Cu(Phe-Phe)(phen)] the most lipophilic. Besides, all the complexes
bind to the DNA, possibly including partial intercalation of the phen
into DNA bases and in the case of the [Cu(Phe-Phe)(phen)] complex
the phenyl side chains of Phe-Phe dipeptidemay also interactwith DNA.
All the complexeswere active against the tested tumor cell lines. The
introduction of phen as a ligand improved the cytotoxic activity as com-
pared to the analog homoleptic Cu–dipeptide complexes. Among all the
studied complexes, [Cu(Ala-Phe)(phen)] showed the strongest cytotox-
ic activity against cancer cell lines and therefore, this compoundmay be
a good candidate to test its antitumor activity in vivo.
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945131 (C5) and CCDC 945306 (C6). ORTEP representations of the
asymmetric unit of the structure of compounds C4–C6 are presented
in Figs. S1–S4. Tables of distances and angles for compounds C4–C6
are presented in tables S1 and S2. Table of speciation is presented in
table S3. EPR spectra and simulations are presented in Fig. S5 and S6.
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Fig. 2.Absorption spectra of [Cu(Ala-Phe)(phen)] in absence and in presence of increasing
amounts of CT-DNA. The arrow indicates de absorbance change upon addition of DNA.
Inset: plot of [DNA] / (εa− εf) vs DNA.
Table 7
Calculated DNA binding constant (Kb).
Compound Kb (M−1)
[Cu(Gly-Val)(phen)] 6.2 × 104
[Cu(Ala-Gly)(phen)] 4.4 × 105
[Cu(Ala-Phe)(phen)] 1.3 × 105
[Cu(Phe-Ala)(phen)] 7.2 × 104
[Cu(Phe-Val)(phen)] 7.0 × 104
[Cu(Phe-Phe)(phen)] 1.5 × 104
Table 8
Calculated albumin binding constant (Kb).
Compound Kb (M−1)
[Cu(Gly-Val)(phen)] 4.3 × 103
[Cu(Ala-Gly)(phen)] 20.0 × 103
[Cu(Ala-Phe)(phen)] 22.5 × 103
[Cu(Phe-Ala)(phen)] 7.4 × 103
[Cu(Phe-Val)(phen)] 4.6 × 103
[Cu(Phe-Phe)(phen)] 13.1 × 103
Table 9
Cytotoxic activity (expressed by IC50) of the studied complexes against HeLa (human
cervical adenocarcinoma), MCF-7 (human metastatic breast adenocarcinoma) and A549
(human lung epithelial carcinoma) cell lines.
Compound IC50(HeLa) μM IC50(MCF-7) μM IC50(A548) μM
[Cu(Gly-Val)(phen)] 15 18 14
[Cu(Ala-Gly)(phen)] 7.5 16 9.5
[Cu(Ala-Phe)(phen)] 2.2 1.0 1.0
[Cu(Phe-Ala)(phen)] 7.7 13 9.9
[Cu(Phe-Val)(phen)] 3.1 7.4 7.1
[Cu(Phe-Phe)(phen)] 5.2 9.6 7.8
[Cu(phen)2]Cl2 16 14 19
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